Chairman Zhou Jie resigns just three months after taking on the role.

Chinese-American diagnostics specialist says it is building a new La Jolla lab to support U.S. product launches.

Lupin may be pondering whether it can conclude a deal signaled in July last year to buy 100% of Russian generic drug maker ZAO Biocom.

Zhejiang Hisun will handle greater China efforts on GEN-1 from Celsion in an expanded partnership aimed at costs and faster approvals.

Mesoblast said its RA candidate MPC-300-IV met safety and toleration goals in a Phase II study for patients who fail to continue to respond to widely used…

Samsung BioLogics is reported to be ready to file an IPO application this week in South Korea that is seen raising more than $2 billion.

China unexpectedly rebounded for Novo Nordisk in the second quarter as human insulin sales gained pace in a highly competitive market.

Pfizer executives spent considerable time on the second-quarter earnings call discussing biosimilar plans related to China and South Korea's Celltrion.